• Health & Medicine

Docetaxel significantly increases survival for incurable gastric cancers

Survival for advanced stomach and oesophagael cancer patients increases by 40 per cent when treated with the chemotherapy drug, Docetaxel – providing evidence to prescribe it as a second-line treatment, according to the results of a Cancer Research UK trial presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal cancers symposium today. Survival for advanced stomach and oesophagael cancer patients increases by 40 per cent when treated with the chemotherapy drug, Docetaxel – providing evidence to prescribe it as a second-line treatment, according to the results of a Cancer Research UK trial presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal cancers symposium today.

23 January 2013

• Health & Medicine
• Science & Technology

Genetic link to Barrett's oesophagus identified for first time

UK scientists have discovered the genetic basis for why some people are more at risk of developing Barrett's oesophagus, a condition that increases the risk of oesophageal cancer. UK scientists have discovered the genetic basis for why some people are more at risk of developing Barrett's oesophagus, a condition that increases the risk of oesophageal cancer.

10 September 2012

Trial launch of urgently-needed combination treatment for oesophago-gastric cancer

Cancer Research UK’s Drug Development Office (DDO), in collaboration with academia and industry, has announced a new trial to open in Oxford. The trial will test an experimental drug from AstraZeneca in patients with advanced oesophago-gastric cancer – a disease for which no well-established standard treatments exist. Cancer Research UK’s Drug Development Office (DDO), in collaboration with academia and industry, has announced a new trial to open in Oxford. The trial will test an experimental drug from AstraZeneca in patients with advanced oesophago-gastric cancer – a disease for which no well-established standard treatments exist.

17 August 2012

• Health & Medicine

Cancer Research UK launches trial of experimental drug combination for advanced stomach and oesophageal cancer

Cancer Research UK’s Drug Development Office (DDO) has joined forces with academia and industry to open a clinical trial that will test an experimental drug from AstraZeneca called AZD4547 in combination with standard chemotherapy to treat a group of patients with advanced stomach or oesophageal cancer. Cancer Research UK’s Drug Development Office (DDO) has joined forces with academia and industry to open a clinical trial that will test an experimental drug from AstraZeneca called AZD4547 in combination with standard chemotherapy to treat a group of patients with advanced stomach or oesophageal cancer.

8 June 2012

• Health & Medicine

A minimum alcohol price could cut cancer rates

28 March 2012

• Health & Medicine

Aspirin and cancer - the picture becomes clearer

21 March 2012

• Health & Medicine

Spotting cancer early - our partnership with Tesco

6 March 2012

• Science & Technology

New video: Cracking the cancer code

4 March 2012

• Science & Technology
• Health & Medicine

Podcast: New drugs, earlier diagnosis, and an interview with our chief executive

14 February 2012

• Science & Technology
• Health & Medicine

News digest – oesophageal cancer, HRT, Leveson and more

21 January 2012

Fluorescent dye pinpoints tiniest signs of oesophageal cancer

A fluorescent dye that can be sprayed onto the oesophagus - the food pipe - could be used to detect oesophageal cancer earlier and spare patients unnecessary treatment, according to research published today in Nature Medicine. A fluorescent dye that can be sprayed onto the oesophagus - the food pipe - could be used to detect oesophageal cancer earlier and spare patients unnecessary treatment, according to research published today in Nature Medicine.

15 January 2012

• Health & Medicine

Bowel, oesophageal and pancreatic cancers show biggest improvement in diagnosis time

Research shows that patients are, on average, being diagnosed more quickly for some cancers, offering a better chance of successful outcome. Research shows that patients are, on average, being diagnosed more quickly for some cancers, offering a better chance of successful outcome.

8 November 2011